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Abstract
Cytomegalovirus (CMV) is one of the most common opportunistic viruses in human immunodeficiency virus 
(HIV)-infected patients. The aim of this study was to determine the CMV seroprevalence among HIV-infected 
patients and investigate the correlation between the CMV immunoglobulin G (IgG) antibody titers and cluster of 
differentiation 4 (CD4) T-cell counts, as well as highly active antiretroviral therapy (HAART) use. Serum samples 
from 69 HIV-infected patients and 65 HIV-seronegative persons attending Dr. Hasan Sadikin General Hospital 
Bandung in March–June 2012 were examined to detect CMV IgG antibody using electrochemiluminescence 
immunoassay (ECLIA). Data were analyzed using chi-square test, t-tests and analysis of variance (ANOVA). The 
results show that there were no statistically significant differences in the seroprevalence of CMV between HIV-
infected (97%) and HIV-seronegative persons (94%). The mean of CMV IgG antibodies titers in HIV-infected 
patients (335.39+174.87 U/mL) were significantly higher than that of HIV-seronegative persons (240.59+192.76 
U/mL). There was no significant correlation between CMV IgG antibody titers and CD4 T-cell counts (the mean 
was 393.58+209.22 cells/mm3). The titers of CMV IgG antibodies were significantly inversely associated with 
HAART use. The mean of CMV IgG antibody titers in HIV-infected patients on HAART (335.41+172.98 U/mL) 
were significantly higher than patients without HAART (204.8+213.91 U/mL). In conclusions, this study confirms 
a high seroprevalence of CMV among HIV-infected patients. High titers of CMV are inversely associated with 
HAART use while no correlation with CD4 T-cell counts was found. [MKB. 2013;45(2):112–7] 
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Studi Serologi Cytomegalovirus pada Pasien yang Terinfeksi HIV 
di Era Highly Active Antiretroviral Therapy
Abstrak
Cytomegalovirus (CMV) adalah salah satu virus oportunistik yang paling umum pada pasien yang terinfeksi human 
immunodeficiency virus (HIV). Tujuan penelitian ini untuk mengetahui seroprevalensi CMV pada pasien HIV dan 
meneliti korelasi antara titer antibodi imunoglobulin G (IgG) CMV dan jumlah sel-T cluster diferensiasi 4 (CD4) 
serta penggunaan highly active antiretroviral therapy (HAART). Sampel serum dari 69 pasien HIV dan 65 HIV-
seronegatif yang berkunjung ke Rumah Sakit Dr. Hasan Sadikin Bandung pada bulan Maret–Juni 2012 diperiksa 
untuk mendeteksi antibodi IgG CMV dengan immunoassay electro chemiluminescence (ECLIA). Data dianalisis 
dengan menggunakan uji chi-kuadrat, t, dan analysis of variance (ANOVA). Hasil penelitian menunjukkan tidak 
ada perbedaan yang signifikan antara seroprevalensi CMV pada pasien HIV (97%) dan HIV-seronegatif (94%). Titer 
antibodi rata-rata IgG CMV pasien HIV (335,39+174,87 U/mL) signifikan lebih tinggi daripada HIV-seronegatif 
(240,59+192,76 U/mL). Tidak ada hubungan yang signifikan antara titer antibodi IgG CMV dan jumlah sel-T 
CD4 (rata-rata 393,58+209,22 sel/mm3). Titer antibodi IgG CMV secara signifikan berhubungan terbalik dengan 
penggunaan HAART. Titer antibodi IgG CMV rata-rata pasien HIV dengan HAART (335,41+172,98 U/mL) 
signifikan lebih tinggi dibandingkan dengan pasien tanpa HAART (204,8+213,91 U/mL). Simpulan, penelitian 
ini menegaskan seroprevalensi CMV pasien HIV dan titer antibodi IgG CMV yang tinggi berhubungan terbalik 
dengan penggunaan HAART tetapi tidak berkorelasi dengan sel-T CD4. [MKB. 2013;45(2):112–7] 
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Introduction
The human cytomegalovirus (CMV) which is a 
beta-herpes virus is considered the most important 
viral opportunistic pathogen in patients with 
acquired immune deficiency syndrome (AIDS). 
Epidemiological studies showed that infections 
caused by CMV occur frequently across countries 
in the world and CMV seroprevalence in general 
population is estimated to range between 60% and 
90% in developed countries, even higher rates 
(>90%) in developing countries.1 Seroprevalence 
of CMV infection in human immunodeficiency 
virus (HIV)-infected patients is also high, ranging 
from 50% to above 90%.1-3 Detectable CMV viral 
loads are associated with increased mortality, 
even in the era of highly active antiretroviral 
therapy (HAART).4
Although primary infection with CMV does 
not generally produce symptoms in healthy 
individuals, the infection may cause more serious 
and potentially life-threatening illnesses among 
HIV-infected patients. Cytomegalovirus retinitis 
is the most common serious ocular complication 
in HIV-infected patients, which occurs in 40% 
of AIDS patients.5,6 In addition, CMV infection 
causes diseases in several organ systems such as 
the central nervous system (CNS), gastrointestinal 
(GI) tract and pneumonitis.6-9 
The majority of diseases relate to reactivation 
of latent infection. Most cases of CMV disease 
occur in HIV-infected patients with advanced 
immunosuppression. The HIV-infected patients 
with cluster of differentiation 4 (CD4) T-cell 
counts <100 cells/mm3 are at significant risk for 
CMV reactivation leading to invasive disease.10 
Prior to the development of HAART, CMV 
disease occurred in 10.9% of patients with AIDS.6 
The introduction of HAART has led to changes 
in the incidence of CMV diseases.5 It has been 
reported that CMV disease may occur during 
immune recovery in the HAART era.9,11,12
Considering the above facts, this study was 
undertaken to assess the seroprevalence of CMV 
and to measure the titers of CMV IgG antibody 
against CMV and its association with CD4 and 
the use of HAART among HIV/AIDS patients. 
These data may have important implications with 
regard to the transmission of CMV. 
Methods
The present study was carried out among 69 
HIV-infected patients and 65 HIV-seronegative 
persons who visit a major referral hospital, Dr. 
Hasan Sadikin Hospital, Bandung, Indonesia. 
The HIV-seronegative persons were matched 
to HIV-infected patients based on age and sex 
as a control group. The use of highly active 
antiretroviral therapy was recorded from medical 
records. 
Blood samples were collected from all 134 
study participants and sera were separated and 
stored at -20 ˚C until testing. The HIV status was 
confirmed by enzyme-linked immunosorbent assay 
(ELISA). The CD4 cell counts were measured by 
the Becton Dickenson fluorescence-activated cell 
sorter (BD FACSCount™) cytometer according to 
the manufacturer's instructions. Serum anti-CMV 
was determined by a commercially available test 
kit, the Elecsys CMV immunoglobulin G (IgG) 
assay (Roche Diagnostics) in accordance with 
the manufacturer's instructions. Positive and 
negative standard sera, accompanying the kit 
were included in each assay. 
The results were then analyzed statistically 
using the statistical package for social sciences 
(SPSS) version 11.0 for Windows.  The mean ± 
standard deviation (SD), median and ranges were 
calculated and proportion, as well as frequency 
tables were used to summarize the categorical 
variables. The student t-test was used to compare 
age distribution for both groups. Differences in 
CMV seropositivity rates among different groups 
were evaluated using the chi-square test. Mean 
titer levels were compared between HIV-infected 
and HIV-seronegative controls using two sample 
t-tests. The statistical significance of CMV IgG 
antibody titers with other associated factors (CD4 
and HAART use) was obtained using univariate 
analysis of variance (ANOVA). The p value 
<0.05 was taken as the level of significance. 
All participants gave written informed consent 
for participation. Ethical clearance was obtained 
from the Health Research Ethics Committee of 
Dr. Hasan Sadikin General Hospital/Faculty of 
Medicine of Universitas Padjadjaran, Bandung, 
Indonesia. 
Results 
Overall, a total of 69 patients with HIV infection 
(34 males and 35 females) took part in the study. 
The age ranged from 22–55 years, with the mean 
age 32+5 years, median 32 years. The control 
group consisted of 34 HIV-seronegative males 
and 31 HIV-seronegative females with the mean 
age of 29.1+12.1 years (median 28 years, range 
1–56 years). There was no significant statistical 
difference between HIV-infected patients and 
the control group in age (p>0.05) and gender 
distributions (p>0.05) (Table 1). 
Out of 69 of the HIV-infected patients, 97% 
were seropositive for CMV IgG antibodies, 
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Table 1 Age and Gender of Study Participants
Characteristics HIV-seronegative 
(n=65)
HIV-infected 
(n=69)
p
Age
Mean+SD (range) +5 (22–55) 31+10 (17–58) >0.05
Median 32 29
Gender
Female 31 35 >0.05
Male 34 34
Note: n=number of subjects; SD=standard deviation; *p<0.05, statistically significant
Figure 1 Seroprevalence of CMV among 
   HIV-Infected Patients and HIV  
   Seronegative Persons
Figure 2 Distribution of CMV Seropositive 
   by  the Rate of CD4 T-cell Counts 
   among HIV-Infected Patient
Table 2 The Titers of Cytomegalovirus IgG Antibody
Characteristics HIV-seronegative 
(n=65)
HIV-infected 
(n=69)
p
Mean 240.59 335.39 >0.05
SD 192.76 174.87
Median 170.7 403
Note: n=number of subjects; SD=standard deviation; *p<0.05, statistically significant
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slightly higher than the 94% in HIV-seronegative 
persons. The difference was not statistically 
significant (p>0.05). We found only 6% of HIV-
seronegative persons and 3% of HIV-positive 
persons with a negative test result for CMV IgG 
antibody (Figure 1).
Immunoglobulin G antibodies against CMV 
are more frequently found in HIV-infected 
patients with a CD4 cell count of more than 500 
cells/ mm3 (Figure 2). No significant correlation 
was observed between the CMV IgG antibody 
titers and CD4 counts (Table 3). However, the 
titers of CMV IgG antibodies were inversely 
associated with HAART use. It appears that the 
CMV IgG antibody titers in HIV-infected patients 
on HAART are higher than those of HIV-infected 
without HAART. 
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Discussion
Our study demonstrates that IgG antibodies 
againts CMV were high in both HIV-infected 
and HIV-seronegative persons and the difference 
between the two groups was not statistically 
significant. Our findings are consistent with 
earlier studies which found that there was no 
statistically significant difference between CMV 
seroprevalence in HIV-infected patients and 
HIV-seronegative persons.13 Cytomegalovirus 
is well known as an extremely common virus 
worldwide. The seroprevalence of CMV varies 
worldwide, and is related to geographic, ethnic 
and social factors.14 The reason for the high 
seroprevalence of CMV in general population 
is that CMV primarily spread through close 
interpersonal contact with infected blood and 
body fluids including saliva, urine, breast milk, or 
genital secretions. Cytomegalovirus is also able to 
cross the placental barrier. As a result, CMV can 
be transmitted in any way that involves passing 
secretions. This includes sexual contact, blood 
transfusion, organ transplant and breastfeeding. 
We found almost all HIV-infected patients 
(97%) had IgG antibodies to CMV. This study 
also confirms previous results showing the high 
seroprevalence of CMV IgG antibodies in HIV-
infected patients. Interestingly, when we did 
an analysis to compare IgG antibody titers, the 
results showed significantly higher IgG antibody 
titers against CMV in HIV-infected patients 
compared to HIV-seronegative persons. The high 
seroprevalence of CMV in HIV-infected patients 
is related to sexual activity. A previous study 
has identified sexual activity and behaviors as 
important risk factors for acquiring CMV among 
HIV-infected patients. Another study also found 
that significant risk factor for CMV infections was 
homosexual or bisexual orientation.15 Another 
study reported that the maximum prevalence of 
CMV antibody was seen in HIV-infected patients 
with unsafe sex and intravenous drug users 
(IDUs).3 
It has been stated that CMV diseases are 
associated with a compromised immune system 
in HIV-infected patients. The disease typically 
occurs in HIV-infected patients with a CD4 count 
of <50 to 100 cells/mm3.16 A study indicated 
that insufficient help of CD4+ T cells in HIV-
1–Infected patients may cause loss of control 
of CMV dissemination.10 However, it has also 
been reported that CMV disease occurred in 
patients with a CD4 count of >100 cells/ mm3.17 
The presence of CMV antibody does not appear 
to be associated with the clinical stage of HIV-
1 infection, suggesting that a higher CD4 T-cell 
count does play a role in immunity against CMV 
infection. Our findings showed no significant 
correlation between the titer of all three viruses 
and CD4 cell counts. However, we can see that 
most HIV-infected patients who were CMV 
seropositive had a CD4 count of >500 cells/mm3. 
Analysis of the data indicated a statistically 
significant inverse association between the titer 
of CMV IgG antibody and treatment of HIV-
infected patients on HAART. We observed higher 
CMV IgG antibody titers in patients on HAART 
compared to those in patients without HAART. 
This higher cytomegaloviremia in HIV patients 
was associated with higher mortality during 
the pre-HAART era. However, in the HAART 
era, it has been reported that CMV disease may 
occur during immune recovery. Our data show 
that CMV IgG antibodies in HIV patients on 
HAART were detected more often in patients 
with a mean CD4 cell count of >500 cells/
mm3. These findings suggest that higher titer of 
Tabel 3 The Titers of Cytomegalovirus IgG Antibody and CD4 T-cell Counts among HIV-
  Infected Patients
The Titers of CMV IgG Antibody
Mean (U/mL) SD p
CD4 T-cell counts
<200 264.15 184.87 >0.05
200–349 344.90 184.97
350–499 332.21 161.90
>500 364.77 176.07
HAART use
on HAART 335.41 172.98 <0.05
without HAART 197.87 188.14
Note: SD=standard deviation; *p<0.05, statistically significant
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cytomegalovirus IgG antibody after antiretroviral 
therapy may also be associated with immune 
restoration inflammatory syndrome (IRIS). It 
has been suggested that IRIS through HAART 
may be a key component of CMV infection. 
Immune restoration inflammatory syndrome may 
occur in HIV-infected persons, ranging from 
less than 10% to more than 50%, after starting 
HAART when there is a surge in reconstitution of 
effector and regulatory T cells.18,19 A prior study 
demonstrated that CMV retinitis after HAART is 
associated with increased plasma levels of IgG 
anti-CMV antibody.11 The immunopathological 
process underlying IRIS is not fully understood 
yet. Therefore, it is suggested that the syndrome 
is the result of exaggerated and dysregulated 
cellular immune responses that depend on the 
associated pathogen.19,20 In viral infections such 
as infections caused by cytomegalovirus, CD8+ 
T cells in particular are involved in protection and 
immunopathology.11,20  
In conclusion, this study has identified that 
infection with CMV is very common both in 
general population and in HIV-infected patients. 
High titers of CMV among HIV-infected patients 
are inversely associated with HAART use but 
no correlation with the CD4 T-cell count is 
found. It is difficult to identify an acute CMV 
infection because the disease is almost always 
asymptomatic and usually presents nonspecific 
clinical signs. Nevertheless, the CMV has been 
known as poses major health problems as it may 
cause serious morbidity and mortality in HIV-
infected patients. Hence, these findings underline 
the importance of prevention strategies to reduce 
CMV disease and CMV-associated immune 
recovery syndrome.
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